Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026. Recent clinical data shows RGX-121 can address neurological decline, a major ...
The last time I spoke about REGENXBIO Inc. (RGNX) it was in a Seeking Alpha article entitled "Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder". Regarding this article, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results